Grazoprevir/Elbasvir

ApprovedSmall molecule

Merck & Co.

Grazoprevir/Elbasvir is one of 89 small molecule programs targeting Chronic Hepatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Kidney TransplantActive, not recruiting

Hepatitis CActive, not recruiting

Chronic HepatitisPhase 3

Active, not recruiting

Kidney TransplantApproved

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

Grazoprevir/Elbasvir

Merck & Co.

Approved

1 2

PEG-Intron

Merck & Co.

Preclinical

43 3

Sovaldi

Gilead

Preclinical

34 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Intron a

Sanofi

Preclinical

7 7

Roferon-a

Roche

Preclinical

3 8

Medrol

Pfizer

Preclinical

1 9

Dasabuvir

AbbVie

Preclinical

7 10

SOF/VEL

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis C3 trials

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

Completed·IInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba·Phase 2·NCT02886624·30 enrolled

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02251990·489 enrolled

Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs

Terminated·KKirby Institute·Phase 4·NCT02940691·32 enrolled

Chronic Hepatitis1 trial

Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 3·NCT02204475

Acute1 trial

Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV

Completed·EErasmus Medical Center·Phase 3·NCT02600325·80 enrolled

Resectable1 trial

the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.

Unknown status·TTel-Aviv Sourasky Medical Center·N/A·NCT03110055·20 enrolled

Efficacy and Safety1 trial

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

Completed·AANRS, Emerging Infectious Diseases·Phase 2·NCT02647632·26 enrolled

1 more indication

Kidney Transplant1 trial

Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant

Unknown status·KKing Faisal Specialist Hospital & Research Center·Phase 4·NCT03359746·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Grazoprevir/Elbasvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Grazoprevir/Elbasvir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Grazoprevir/Elbasvir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Grazoprevir/Elbasvir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis C3 trials

Chronic Hepatitis1 trial

Acute1 trial

Resectable1 trial

Efficacy and Safety1 trial

Kidney Transplant1 trial

References

Drug Info

Quick Facts

Related News